Upcoming Allied Market Research
Muscular Dystrophy Drugs Market

Muscular Dystrophy Drugs Market

by Drugs (Corticosteroids, Eteplirsen, Golodirsen, Cardiovascular Medication, Others), by Route of Administration (Oral, Parenteral, Others) by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A50481
Pages: NA
May 2023 | 30 Views
Author(s) : Onkar S
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

Muscular dystrophy (MD) is a group of rare neuromuscular diseases that causes gradual weakening and loss of muscular mass. It is caused due to the interference of some abnormal genes with the production of proteins required for healthy muscles. There are over 30 different types of MD disorders that may be present at birth or appear during childhood or adulthood. Currently, there is no cure for this disease, but therapy and medications may help to control the symptoms. Various drugs like corticosteroids, creatine supplements, and heart medicines are prescribed for strengthening the muscles.
The muscular dystrophy drugs market is projected to witness strong growth in the upcoming years. This can majorly be attributed to the increase in various experiments and clinical trials conducted by the pharmaceutical industries. These trials focus on the development of potential treatments for MD. One of the most common types of MD, called Duchenne muscular dystrophy (DMD) can be treated with the help of exon-skipping therapy. Exons are part of a DNA that are involved in coding for proteins. This therapy prevents the mutation of the genes, by skipping over the exon responsible for the disease. Since it has shown favorable results, this therapy may also help to drive the market. As there is no permanent cure for MD, available treatments primarily focus on the management of symptoms. The development of more efficacious drugs for the treatment of MD, with fewer side effects, will fuel this market in the upcoming years. There is an unmet need for these drugs, driving the research and development organizations. There has been an increasing prevalence of MD in the last few years. Some factors like increased awareness among the people and better diagnostic methods may also act as a driver for this market.
The MD market may witness some challenges, restricting its growth. Most of the drugs used to treat MD have a high cost. This can act as a barrier for a large group of patients who cannot afford expensive medication. These drugs have limited efficacy that differs from patient to patient. Drugs may be effective in certain types of diseases only. This makes it challenging to find an effective cure for a particular type of MD. Also, there are various regulatory barriers to the development of drugs for rare diseases like this. Since it is a rare disease, a small population is affected by MD. Therefore, there is minimal investment in research and development for this drugs.
The market share for MD drugs is anticipated to witness several new opportunities in the forthcoming years. Novel treatment strategies like the advent of gene therapy techniques and stem cell therapy may provide significant breaks for the key players in the market. Many companies are now attempting to develop innovative strategies and improve the therapies already in use. Because of the rising incidence, the government is interested in funding various research and clinical trials as well as raising public awareness. This has caused an increase in the research and development programs for MD drugs. Owing to these factors, the market is expected to grow during the forecast period.
New product trends to flourish in the market
In August 2020 U.S. FDA approved, Zolgensma, the first gene therapy for the treatment of MD. In recent years, gene therapy has become a promising approach for MD. This treatment makes use of a virus to deliver a copy of a particular gene, namely the SMN1 gene to patients suffering from spinal muscular atrophy. Other than this, various combination therapies are under study for more favorable outcomes. For instance, the combination of exon-skipping therapy with gene therapy is under clinical trials.
Segment overview
By drugs: The MD market is classified as corticosteroids, eteplirsen, golodirsen, cardiovascular medication, and others. Prednisone and deflazacort are the most common types of corticosteroids prescribed for MD. These drugs work by strengthening the muscles, thus delaying the progression of certain types of MD. Eteplirsen is recommended for children suffering from DMD. Corticosteroids are the most commonly prescribed drugs and are thus expected to dominate the market in the forecast period.
By route of administration: The MD market is divided into oral, parenteral, and others. The oral route is one of the most common types of routes due to patient compliance and ease of administration. Corticosteroids are typically administered orally. Parenteral routes include intravenous, intramuscular, or subcutaneous injections. Out of these, IV injections show the fastest effect as the drug is directly injected into the veins.
By distribution channel: The MD market is categorized as hospital pharmacy, online pharmacy, and retail pharmacy. Hospital pharmacies are anticipated to show a higher market share owing to better patient care and access to a range of drugs. Retail pharmacies dispense the medication based on the prescriptions. They may also bloom during the forecast period.
By region: The MD market is segmented into North America, Europe, Asia-Pacific, and LAMEA. The prevalence of MD disease is highest in North America and Europe. Therefore, these segments will dominate the market. Also, several key market players are present in North America, thus fueling the growth of this segment.
Competitive analysis and profiles of the major players in the MD drugs market, such as Bristol Myers Squibb Co., F. Hoffmann La Roche, Fresenius, GlaxoSmithKline, Hikma Pharmaceuticals plc, Mylan Nv, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd, are provided in this report. Some other key market players include Boehringer Ingelheim and Sanofi.

Muscular Dystrophy Drugs Market Report Highlights

Aspects Details
By Drugs
  • Corticosteroids
  • Eteplirsen
  • Golodirsen
  • Cardiovascular Medication
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players Pfizer Inc., F. Hoffmann La Roche, Mylan Nv, Fresenius, Hikma Pharmaceuticals plc, Novartis AG, Teva Pharmaceutical Industries Limited, Bristol Myers Squibb Co., GlaxoSmithKline (GSK), Sun Pharmaceutical Industries Ltd
Boehringer Ingelheim, Sanofi

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Muscular Dystrophy Drugs Market

Start reading.
This Report and over 19,981+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,600
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers